Echo selected for DigitalHealth.London Accelerator programme

Prescription

The medication management app Echo has announced that it has been selected to join the DigitalHealth.London Accelerator’s second cohort.

The Accelerator, part-funded by the European Regional Development Fund, was developed to raise awareness for the NHS into potential digital health companies whose products can benefit patients.

Echo has been selected out 127 applicants to join the second cohort of the Accelerator’s programme.

Echo lets patients order repeat prescriptions from EPS-enabled, NHS England GPs so they can have medication delivered free to their door by the Royal Mail. Users are also reminded when to take their medication and also when they’re about to run out.

An analysis of 3,000 Echo users found that the app helped users with medication adherence, with 83.4% found to be adherent, a 66% improvement on WHO adherence estimates for developed countries.

Hannah Harniess, programme director, DigitalHealth.London Accelerator said: “The 21st Century NHS faces unprecedented challenges. Better use of technology is crucial to creating a health system fit for the future and the DigitalHealth.London Accelerator programme is pioneering in bridging the gap between high-calibre digital health innovations and the health system. We are hugely excited to welcome our second cohort of digital innovations to the programme and look forward to connecting solutions such as Echo to areas of need within the system for the next year.”

Sai Lakshmi, CEO Echo, said: “We are thrilled to have been selected for this accelerator which offers the industry specific support and connections needed to help scale Echo to maximise benefits and savings for the NHS, doctors and patients. Echo is already having huge impact on adherence and we look forward to expanding our reach with partners across the NHS to build on this momentum.”



'Echo selected for DigitalHealth.London Accelerator programme' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

© 2017 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions